Cancer-related cognitive impairment studies
Cancer-related cognitive impairment studies is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 12k research works in it since 1951. 22.0% of them reached the world's top 10% most cited for their field and year.
This cluster of papers explores the mechanisms and impact of chemotherapy-induced cognitive impairment in cancer patients, particularly focusing on breast cancer survivors. It covers topics such as the neurobiological basis of cognitive dysfunction, the role of inflammatory cytokines, longitudinal assessment of cognitive changes, and the effects of adjuvant treatments on cognition.
- Chemotherapy
- Cognitive Function
- Breast Cancer
- Neuropsychological Impact
- Adjuvant Treatment
- Cancer Survivors
- Neurobiological Basis
- Inflammatory Cytokines
- Brain Structure
- Longitudinal Study
- Research works
- 12k fractional, since 1951
- In the world top 10%
- 2.6k per year above
- Top-10% rate
- 22.0% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +56% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Cancer-related cognitive impairment studies research?
By volume, the United States and China publish the most (1.1k and 507 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.1k works
- 2 China 507 works
- 3 India 126 works
- 4 United Kingdom 114 works
- 5 Germany 107 works
- 6 Australia 105 works
- 7 Canada 102 works
- 8 Netherlands 99 works
- 9 Italy 98 works
- 10 South Korea 92 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Cancer-related cognitive impairment studies research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Cancer-related cognitive impairment studies research, followed by University of North Carolina at Chapel Hill and Harvard University.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer CenterUnited States 24 works
- 2 University of North Carolina at Chapel HillUnited States 21 works
- 3 Harvard UniversityUnited States 19 works
- 4 Massachusetts General HospitalUnited States 17 works
- 5 The Ohio State UniversityUnited States 16 works
- 6 University of California, San FranciscoUnited States 16 works
- 7 University of PittsburghUnited States 16 works
- 8 Memorial Sloan Kettering Cancer CenterUnited States 13 works
- 9 University of MichiganUnited States 11 works
- 10 Virginia Commonwealth UniversityUnited States 11 works
Who are the leading researchers in Cancer-related cognitive impairment studies?
The most-cited researchers publishing on Cancer-related cognitive impairment studies include John C. Morris, Ronald C. Petersen and Kaj Blennow.
- 1 John C. Morris United States 5.1k citations
- 2 Ronald C. Petersen United States 4k citations
- 3 Kaj Blennow Sweden 3.4k citations
- 4 David S. Knopman United States 3.2k citations
- 5 Clifford R. Jack United States 3.1k citations
- 6 Henrik Zetterberg Sweden 3.1k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Cancer-related cognitive impairment studies research done?
The largest centres of Cancer-related cognitive impairment studies research in 2022–2025 are Beijing (China), Boston (United States), Seoul (South Korea) and New York (United States).
Largest cities, 2022–2025
Where is the best place to study Cancer-related cognitive impairment studies?
Among universities, judged by research, Chinese University of Hong Kong, Ain Shams University and Harvard University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Chinese University of Hong KongHong Kong | 50.4 | 33.6% | 3.6× | 9 | +89.0% |
| 2 | Ain Shams UniversityEgypt | 47.3 | 28.4% | 4.6× | 11 | +137.9% |
| 3 | Harvard UniversityUnited States | 45.6 | 18.2% | 4.3× | 19 | +81.2% |
| 4 | The University of SydneyAustralia | 44.6 | 37.0% | 2.7× | 9 | +53.7% |
| 5 | University of PittsburghUnited States | 40.9 | 15.8% | 6.0× | 16 | +73.3% |
| 6 | University of California, San FranciscoUnited States | 40.8 | 14.8% | 7.2× | 16 | +13.9% |
| 7 | Washington University in St. LouisUnited States | 40.5 | 27.3% | 3.4× | 8 | +209.3% |
| 8 | Virginia Commonwealth UniversityUnited States | 38.2 | 8.5% | 10.1× | 11 | +58.1% |
| 9 | Chiang Mai UniversityThailand | 35.8 | 14.6% | 8.1× | 9 | — |
| 10 | University of Alabama at BirminghamUnited States | 34.4 | 11.8% | 5.9× | 10 | +249.4% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Cancer-related cognitive impairment studies research growing?
Output in 2018–2022 was 56% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Cancer-related cognitive impairment studies.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.